Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Vijay Peddareddigari et al.|The Lancet Oncology|2012Cited by 541
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerMohamed A. Gouda, Funda Meric‐Bernstam, Martin H. Voss et al.|ESMO Open|2025Cited by 54
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ryan B. Corcoran, Eric Van Cutsem, Thierry André et al.|Annals of Oncology|2016Cited by 46
LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)Eric Van Cutsem, Ryan B. Corcoran, Chloé E. Atreya et al.|Annals of Oncology|2015Cited by 23
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.Pilar Garrido, Ulrik Lassen, Enriqueta Felip et al.|Journal of Clinical Oncology|2014Cited by 4